Asia Health and Biopharma News Roundup

Well-Known Scientist Resigns Abruptly Three Months into Appointment

Liu Yongjun, the former Sanofi Head of Global R&D and Executive VP at Innovent Bio, has resigned from his post as Executive President and Head of Global R&D at CSPC, a large public pharmaceutical company in China. Liu had assumed the role just three months earlier, on September 9.

While the reasons for his resignation have not been officially disclosed, there is speculation surrounding the culture clash and the series of changes that Liu had initiated during his tenure, which may not have been fully embraced or implemented within the company.

India Pharma Market Shows Nearly Double-Digit Growth in Volume in November

New data from Pharmarack, a market research firm, reveals that the Indian pharma market saw a growth of 9.9% in value and 3.1% in volume during November. This marks a positive turnaround, especially after four months of relatively weaker performance in terms of volume growth.

Several key therapy areas drove the growth, particularly in acute and chronic segments like cardiac, gastrointestinal, anti-diabetes, and dermatology. The antineoplastics category saw the fastest volume growth, at 11.8%.

This growth is seen as a sign of recovery and increasing demand, particularly as healthcare needs remain elevated across these therapeutic areas.